Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?

Pierre Delanaye1, Toralf Melsom2, Natalie Ebert3, Sten-Erik Bäck4, Christophe Mariat5, Etienne Cavalier6, Jonas Björk7, Anders Christensson8, Ulf Nyman9, Esteban Porrini10, Giuseppe Remuzzi11,12, Piero Ruggenenti11,12, Elke Schaeffner3, Inga Soveri13, Gunnar Sterner14, Bjørn Odvar Eriksen2 and Flavio Gaspari15

1Department of Nephrology, Dialysis and Transplantation, University of Liège Hospital (ULg CHU), 4000 Liège, Belgium, 2Metabolic and Renal Research Group, UiT The Arctic University of Norway and Section of Nephrology, University Hospital of North Norway, Tromsø, Norway, 3Charité University Medicine, Institute of Public Health, Berlin, Germany, 4Department of Clinical Chemistry, Skåne University Hospital, Lund, Sweden, 5Department of Nephrology, Dialysis, Transplantation and Hypertension, CHU Hôpital Nord, University Jean Monnet, PRES Université de LYON, Saint-Etienne, France, 6Department of Clinical Chemistry, University of Liège Hospital (ULg CHU), Liège, Belgium, 7Department of Occupational and Environmental Medicine, Lund University, Lund, Sweden, 8Department of Nephrology, Skåne University Hospital, Lund, Sweden, 9Department of Translational Medicine, Division of Medical Radiology, Skåne University Hospital, Malmö, Sweden, 10University of La Laguna, CIBICAN-ITB, Faculty of Medicine, Hospital Universtario de Canarias, Tenerife, Spain, 11Centro di Ricerche Cliniche per le Malattie Rare ‘Aldo e Cele Daccò’, Istituto di Ricerche Farmacologiche Mario Negri, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy, 12Unit of Nephrology, Azienda Socio Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy, 13Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 14Department of Nephrology, Skåne University Hospital, Malmö, Sweden and 15IRCCS - Istituto di Ricerche Farmacologiche ‘Mario Negri’, Centro di Ricerche Cliniche per le Malattie Rare ‘Aldo e Cele Daccò’, Ranica, Bergamo, Italy

Correspondence and offprint requests to: Pierre Delanaye; E-mail: pierre_delanaye@yahoo.fr

Received: May 18, 2016. Accepted: July 11, 2016

© The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Abstract

A reliable assessment of glomerular filtration rate (GFR) is of paramount importance in clinical practice as well as epidemiological and clinical research settings. It is recommended by Kidney Disease: Improving Global Outcomes guidelines in specific populations (anorectic, cirrhotic, obese, renal and non-renal transplant patients) where estimation equations are unreliable. Measured GFR is the only valuable test to confirm or confute the status of chronic kidney disease (CKD), to evaluate the slope of renal function decay over time, to assess the suitability of living kidney donors and for dosing of potentially toxic medication with a narrow therapeutic index. Abnormally elevated GFR or hyperfiltration in patients with diabetes or obesity can be correctly diagnosed only by measuring GFR. GFR measurement contributes to assessing the true CKD prevalence rate, avoiding discrepancies due to GFR estimation with different equations. Using measured GFR, successfully accomplished in large epidemiological studies, is the only way to study the potential link between decreased renal function and cardiovascular or total mortality, being sure that this association is not due to confounders, i.e. non-GFR determinants of biomarkers. In clinical research, it has been shown that measured GFR (or measured GFR slope) as a secondary endpoint as compared with estimated GFR detected subtle treatment effects and obtained these results with a comparatively smaller sample size than trials choosing estimated GFR. Measuring GFR by iohexol has several advantages: simplicity, low cost, stability and low interlaboratory variation. Iohexol plasma clearance represents the best chance for implementing a standardized GFR measurement protocol applicable worldwide both in clinical practice and in research.

Key words: glomerular filtration rate, iohexol

Introduction

The first part of this review article focused on practical and technical aspects of iohexol plasma clearance [i.e. plasma iohexol analysis and clearance investigation procedures (number of samples and timing)]. In this second part, we focus on the indication of glomerular filtration rate (GFR) measurements in clinical practice as well as in epidemiological and clinical research.

Role of iohexol in clinical practice

It is beyond the scope of this article to review and summarize all clinical settings where measured GFR is recommended [1–3]. Briefly, and as stated in the Kidney Disease: Improving Global Outcomes guidelines [4], additional tests for GFR assessment are needed in specific populations where creatinine-based equations are unreliable, because serum creatinine is largely dependent on muscle mass [5]. Cystatin C can be used as an alternative test but is influenced by other non-GFR-related factors such as obesity, thyroid function and cardiovascular risk factors [6–11]. Thus, measured GFR is recommended for specific patients or subjects with an abnormal muscle mass or body composition, such as anorectic, cirrhotic, obese and renal and non-renal transplant patients [2, 12–17]. If, in daily practice, repeated measurements of GFR in these patient groups are infeasible, at least one GFR measurement will indicate the relationship between serum creatinine (or plasma cystatin C) concentrations and the ‘true’ GFR level. Measured GFR is the only available test to certify GFR levels, and according to the GFR level, to confirm or refute chronic kidney disease (CKD) status. Also, in longitudinal studies, several authors have described the limitations of estimated GFR (eGFR) to adequately assess the true decline in measured GFR [17–21].

Another clear indication for GFR measurement applies when an exact value of GFR is required [4]. The two typical examples are the measurement of GFR before potential living kidney donation or before prescribing a potentially toxic hydrosoluble drug with a narrow therapeutic window, e.g. aminoglycosides or cisplatin [1, 22–24]. Finally, without measured GFR, one pathological condition in nephrology would remain undetected. Abnormally elevated GFR, or hyperfiltration, has been established as an initial pathophysiological step to CKD in patients with diabetes and may also be of importance in common conditions such as obesity, metabolic syndrome and prediabetes [25, 26]. Importantly, data suggest that treating hyperfiltration with angiotensin-converting enzyme inhibitors could be beneficial [27, 28]. However, it is well accepted that the condition of hyperfiltration can only be correctly detected with measured GFR, as all eGFR equations perform poorly in this specific, highly relevant pathological state [16, 17, 22].

Role of iohexol in clinical research

The role of measured GFR in both clinical epidemiology and clinical research is another important objective of this review.

Clinical epidemiology

Measuring GFR is also feasible in large epidemiological studies. For example, the CRIC (Chronic Renal Insufficiency Cohort), BIS (Berlin Initiative Study), AGES-II (Age, Gene/Environment Susceptibility) and RENIS (Renal Iohexol Clearance Survey) studies are four large observational cohorts with GFR measured by iothalamate (CRIC) and iohexol (BIS, AGES-II and RENIS) [29–33]. The RENIS study is interesting since it is a European observational study with a representative sample of the general population in Tromsø, Norway, and GFR measurement has been repeated in the follow-up [26, 31]. The BIS study also measured GFR with iohexol plasma clearance in a large population-based cohort of older patients (mean age 79 years), which also proves the feasibility of performing measured GFR in this fragile age group [32, 34].

Data from numerous epidemiological studies show high but different prevalence rates of CKD in the general population. Moreover, CKD status is associated with mortality, especially cardiovascular mortality [8, 35–38]. However, the vast majority of these epidemiological studies are based on eGFR. It is known that all eGFR equations, based on creatinine and/or cystatin C, have limitations, particularly at high GFR levels [2, 39, 40]. Also, it has been shown that the prevalence of CKD is largely dependent on the equation [Modification of Diet in Renal Disease (MDRD) versus Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) versus Cockcroft–Gault] and biomarker used (creatinine versus cystatin C) [37, 41]. The major limitations of GFR estimations include issues in calibration of the biomarkers [42], different performance of the estimators according to age [43].
and lack of precision in high GFR values [2]. Even if data are limited, we cannot exclude that the prevalence of CKD in the general population, defined as GFR < 60 mL/min/1.73 m², may be much lower with measured GFR compared with eGFR [31].

The higher risk of mortality associated with decreased GFR is another hot topic in clinical epidemiology [4, 36, 44]. Once again, associations between cardiovascular risk and CKD have been described with eGFR in the vast majority of patients. This fact could lead to confusion or false-positive associations, as eGFR may include variables such as gender, ethnicity, weight and age that are per se risk factors for cardiovascular morbidity and mortality and often referred to as ‘non-GFR determinant’. The different weights of these factors in different equations might explain differences in the magnitude of association between cardiovascular outcomes and eGFR [45, 46]. Some authors have suggested a closer association between mortality and the Cockcroft-Gault equation compared with the MDRD study equation [45]. The fact that age is handled differently mathematically in the two equations could explain the discrepancies. The association between eGFR and mortality also varies with the biomarker considered. For cystatin C- versus creatinine-based equations, an increased hazard ratio for all-cause mortality was found for eGFR < 85 mL/min/1.73 m² based on cystatin C, but when the eGFR was based on creatinine, the hazard ratio increased when eGFR was < 60 mL/min/1.73 m² [47, 48].

Also, the classical association between the MDRD (or CKD-EPI) equation and mortality is U-shaped, with a higher mortality at slopes based on measured GFR versus eGFR [17]. The majority of these studies have shown that the decline in measured GFR is underestimated by eGFR. For these reasons, detection of potential differences in GFR slopes between two groups (e.g. one treated with active therapy and the other with placebo) requires larger sample sizes with eGFR than with measured GFR. An example is the trial of belatacept in renal transplant patients, which showed a benefit of belatacept therapy when measured GFR was used, whereas a non-significant difference was observed with eGFR [55]. Importantly, the number of patients with measured GFR in the three groups was relatively small (n = 32 in the intensive belatacept group, n = 37 in the less intensive group and n = 27 in the cyclosporine group). Another illustrative example is the ALADIN (A Long-Acting Somatostatin on Disease Progression in Nephropathy due to Autosomal Dominant Polycystic Kidney Disease) trial in which the efficacy of somatostatin in polycystic kidney disease was studied. The slope of measured GFR was an important secondary endpoint. The authors were able to show that the slope of measured GFR was significantly different between treatment groups (n = 36 and 34 in the active and placebo arm, respectively) [56]. Such important results would have been missed if only eGFR had been used [21]. A similar trial with similar results was published using tolvaptan. The authors also showed a significantly different slope in eGFR after 3 years of follow-up between the tolvaptan and placebo groups, but had to include 1445 patients to detect this significant difference [57].

The lack of precision of eGFR is also particularly important in the context of drug dosage adaptation. It is beyond the scope of this article to discuss all the limitations of equations in this context [58]. Due to these limitations, the European Medicines Agency now recommends that ‘a method accurately measuring GFR using an exogenous marker [should be] used in pharmacokinetic studies in subjects with decreased renal function’ [59].

Conclusions

In conclusion, both in clinical practice and in research, measured GFR is considered too rarely. Nephrology is certainly the only discipline where a gold standard measurement is so uncommonly used. Measuring GFR by iohexol has several advantages: simplicity, low cost, stability and low interlaboratory variation. We are convinced that iohexol plasma clearance is the best chance to implement a standardized GFR measurement protocol that would be applicable worldwide both in clinical practice and in research. Even if it is not as perfect as the ‘gold standard’ method (inulin urinary clearance), iohexol plasma clearance appears to provide the best compromise between physiology, reliability and feasibility.

Clinical research

In nephrological trials, the classic clinical endpoints are mortality, end-stage renal disease or doubling of serum creatinine. However, these are relatively rare events developing over a long period of time, especially in low-risk patients. For this reason, clinical studies in nephrology require large sample sizes and a long follow-up time. Therefore, several authors proposed so-called surrogate markers instead of ‘true’ endpoints. GFR and albuminuria are the two most reliable surrogate markers to use [54]. However, eGFR lacks precision, especially at high GFR levels, and is, as mentioned above, not only dependent on GFR, but also on non-GFR determinants included in the equations. Moreover, several authors have described large discrepancies between slopes based on measured GFR versus eGFR [17–21]. The majority of these studies have shown that the decline in measured GFR is underestimated by eGFR. For these reasons, detection of potential differences in GFR slopes between two groups (e.g. one treated with active therapy and the other with placebo) requires larger sample sizes with eGFR than with measured GFR. An example is the trial of belatacept in renal transplant patients, which showed a benefit of belatacept therapy when measured GFR was used, whereas a non-significant difference was observed with eGFR [55]. Importantly, the number of patients with measured GFR in the three groups was relatively small (n = 32 in the intensive belatacept group, n = 37 in the less intensive group and n = 27 in the cyclosporine group). Another illustrative example is the ALADIN (A Long-Acting Somatostatin on Disease Progression in Nephropathy due to Autosomal Dominant Polycystic Kidney Disease) trial in which the efficacy of somatostatin in polycystic kidney disease was studied. The slope of measured GFR was an important secondary endpoint. The authors were able to show that the slope of measured GFR was significantly different between treatment groups (n = 36 and 34 in the active and placebo arm, respectively) [56]. Such important results would have been missed if only eGFR had been used [21]. A similar trial with similar results was published using tolvaptan. The authors also showed a significantly different slope in eGFR after 3 years of follow-up between the tolvaptan and placebo groups, but had to include 1445 patients to detect this significant difference [57].

The lack of precision of eGFR is also particularly important in the context of drug dosage adaptation. It is beyond the scope of this article to discuss all the limitations of equations in this context [58]. Due to these limitations, the European Medicines Agency now recommends that ‘a method accurately measuring GFR using an exogenous marker [should be] used in pharmacokinetic studies in subjects with decreased renal function’ [59].

Conflict of interest statement

None declared.

References

1. Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009; 20: 2305–2313
2. Delanaye P, Mariat C. The applicability of eGFR equations to different populations. Nat Rev Nephrol 2013; 9: 513–522
3. Gaspari F, Perico N, Remuzzi G. Measurement of glomerular filtration rate. Kidney Int Suppl 1997; 63: S151–S154
4. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1–150
5. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992; 38: 1933–1953
6. Schei J, Stefansson VTN, Mathisen UD et al. Residual associations of inflammatory markers with eGFR after accounting for measured GFR in a community-based cohort without CKD. Clin J Am Soc Nephrol 2016; 11: 2802–2886
7. Knight EL, Verhave JC, Spiegelman D et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416–1421.

8. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038–2047.

9. Stevens LA, Schmid CH, Greene T et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 2009; 75: 652–660.

10. Naour N, Fellahi S, Renucci JF et al. Potential contribution of adipose tissue to elevated serum cystatin C in human obesity. Obesity (Silver Spring) 2009; 17: 2121–2126.

11. Fricker M, Wiesli P, Brandle M et al. Impact of thyroid dysfunction on serum cystatin C. Kidney Int 2003; 63: 1944–1947.

12. Delanaye P, Cavalier E, Radermecker RP et al. Cystatin C or creatinine for detection of stage 3 chronic kidney disease in anorexia nervosa. Nephron Clin Pract 2008; 110: c158–c163.

13. Luis-Lima S, Marrero-Miranda D, Gonzalez-Rinne A et al. Estimated glomerular filtration rate in renal transplantation: the nephrologist in the mist. Transplantation 2015; 99: 2625–2633.

14. Masson I, Flamant M, Maillard N et al. MDRD versus CKD-EPI equation to estimate glomerular filtration rate in kidney transplant recipients. Transplantation 2013; 95: 1211–1217.

15. Beben T, Rifkin DE. GFR estimating equations and liver disease. Adv Chronic Kidney Dis 2015; 22: 337–342.

16. Bouquegneau A, Vidal-Petiot E, Vrtovsik F et al. Modification of Diet in Renal Disease versus Chronic Kidney Disease Epidemiology Collaboration equation to estimate glomerular filtration rate in obese patients. Nephrol Dial Transplant 2013; 28: iv122–iv130.

17. Gaspari F, Ruggenenti P, Porrini E et al. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int 2013; 84: 164–173.

18. Rule AD, Torres VE, Chapman AB et al. Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol 2006; 17: 854–862.

19. Xie Y, Bowe B, Xian H et al. Rate of kidney function decline and risk of hospitalizations in stage 3A CKD. Clin J Am Soc Nephrol 2015; 10: 1946–1955.

20. Gera M, Slezak JM, Rule AD et al. Assessment of changes in kidney allograft function using creatinine-based estimates of glomerular filtration rate. Am J Transplant 2007; 7: 880–887.

21. Ruggenenti P, Gaspari F, Cannata A et al. Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study. PLoS One 2012; 7: e32533.

22. Bouquegneau A, Vidal-Petiot E, Moranne O et al. Creatinine-based equations for the adjustment of drug dosage in an obese population. Br J Clin Pharmacol 2016; 81: 349–361.

23. Pal MP, Nafziger AN, Bertino JS Jr. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother 2011; 55: 4006–4011.

24. Dooley MJ, Poole SG, Rischin D et al. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate. Eur J Cancer 2002; 38: 44–51.

25. Chagnac A, Weinstein T, Krozets A et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000; 278: F817–F822.

26. Melsom T, Schei J, Stefansson VTN et al. Prediabetes and risk of glomerular hyperfiltration and albuminuria in the general nondiabetic population: a prospective cohort study. Am J Kidney Dis 2016; 67: 841–850.

27. Ruggenenti P, Porrini EL, Gaspari F et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 2012; 35: 2061–2068.

28. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996; 49: 1774–1777.

29. Denker M, Boyle S, Anderson AH et al. Chronic Renal Insufficiency Cohort Study (CRIC): overview and summary of selected findings. Clin J Am Soc Nephrol 2015; 10: 2073–2083.

30. Eriksen BO, Melsom T, Mathiesen UD et al. GFR normalized to total body water allows comparisons across genders and body sizes. J Am Soc Nephrol 2011; 22: 1517–1525.

31. Eriksen BO, Mathiesen UD, Melsom T et al. Cystatin C is not a better estimator of GFR than plasma creatinine in the general population. Kidney Int 2010; 78: 1305–1311.

32. Schaeffer ES, Ebert N, Delanaye P et al. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med 2012; 157: 471–481.

33. Inker LA, Okparavero A, Tighiouart H et al. Midlife blood pressure and late-life GFR and albuminuria: an elderly general population cohort. Am J Kidney Dis 2015; 66: 240–248.

34. Schaeffer ES, van der Giet M, Gaedeke J et al. The Berlin initiative study: the methodology of exploring kidney function in the elderly by combining a longitudinal and cross-sectional approach. Eur J Epidemiol 2010; 25: 203–210.

35. Hallan SI, Vikse BE. Relationship between chronic kidney disease prevalence and end-stage renal disease risk. Curr Opin Nephrol Hypertens 2008; 17: 286–291.

36. Matsushita K, van der Velde M, Astor BC et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073–2081.

37. Brück K, Jager KJ, Dounousi E et al. Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review. Nephrol Dial Transplant 2015; 30: iv6–iv16.

38. Brück K, Stel VS, Gambauro G et al. CKD prevalence varies across the European general population. J Am Soc Nephrol 2016; 27: 2135–2147.

39. Eriksen BO, Tomtum J, Ingebretsen OC. Predictors of decline in the nephrologist in the mist. Nephrol Dial Transplant 2016; 31: c41–c50.

40. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612.

41. Delanaye P, Cavalier E, Moranne O et al. Creatinine- or cystatin C-based equations to estimate glomerular filtration in the general population: impact on the epidemiology of chronic kidney disease. BMC Nephrol 2013; 14: 57.

42. Coresh J, Eknoyan G, Levey AS. Estimating the prevalence of low glomerular filtration rate requires attention to the creatinine assay calibration. J Am Soc Nephrol 2002; 13: 2811–2812.

43. Pottel H, Hoste L, Dubourg L et al. A new estimating glomerular filtration rate equation for the full age spectrum. Nephrol Dial Transplant 2016; 31: 798–806.

44. Hallan SI, Matsushita K, Sang Y et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA 2012; 308: 2349.

45. Sederholm Lawesson S, Alfredsson J, Szummer K et al. Prevalence and prognostic impact of chronic kidney disease in
STEMI from a gender perspective: data from the SWEDHEART register, a large Swedish prospective cohort. *BMJ Open* 2015; 5: e008188

46. Matsushita K, Mahmoodi BK, Woodward M et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. *JAMA* 2012; 307: 1941–1951

47. Shlipak MG, Matsushita K, Arnlov J et al. Cystatin C versus creatinine in determining risk based on kidney function. *N Engl J Med* 2013; 369: 932–943

48. Delanaye P, Glassock RJ, Pottel H et al. An age-calibrated definition of chronic kidney disease: rationale and benefits. *Clin Biochem Rev* 2016; 37: 17–26

49. Shlipak MG, Katz R, Sarnak MJ et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. *Ann Intern Med* 2006; 145: 237–246

50. Hsu CY, Propert K, Xie D et al. Measured GFR does not outperform estimated GFR in predicting CKD-related complications. *J Am Soc Nephrol* 2011; 22: 1931–1937

51. Melsom T, Fuskevåg OM, Mathisen UD et al. Estimated GFR is biased by non-traditional cardiovascular risk factors. *Am J Nephrol* 2015; 41: 7–15

52. Mathisen UD, Melsom T, Ingebretsen OC et al. Estimated GFR associates with cardiovascular risk factors independently of measured GFR. *J Am Soc Nephrol* 2011; 22: 927–937

53. Rule AD, Bailey KR, Lieske JC et al. Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease. *Kidney Int* 2013; 83: 1169–1176

54. Coresh J, Turin TC, Matsushita K et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. *JAMA* 2014; 311: 2518–2531

55. Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. *N Engl J Med* 2005; 353: 770–781

56. Caroli A, Perico N, Perna A et al. Effect of long-acting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. *Lancet* 2013; 382: 1485–1495

57. Torres VE, Chapman AB, Devuyst O et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. *N Engl J Med* 2012; 367: 2407–2418

58. Park EJ, Wu K, Mi Z et al. A systematic comparison of cockcroft-gault and modification of diet in renal disease equations for classification of kidney dysfunction and dosage adjustment. *Ann Pharmacother* 2012; 46: 1174–1187

59. EMA. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/02/WC500162133.pdf. 2014](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/02/WC500162133.pdf. 2014)